News

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Eli Lilly (LLY) closed the most recent trading day at $771.75, moving -3.45% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Meanwhile, the Dow ...
Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.
The Lilly Foundation has awarded a grant that will total up to $5.5 million to the Indianapolis Public Schools Foundation to support education programs for science, technology, engineering and ...
IPS middle and high schoolers will soon get to have more hands-on expereince in STEM curriculums and fields as part of a $5.5M Lilly grant.
A new multi-million dollar grant from the Eli Lilly and Company Foundation will help support a new initiative that aims to increase STEM engagement, achievement and career ...
Eli Lilly's LLY -0.28% Get Free Report short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all ...
Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...
The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS ...
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.
The IPS Foundation has received a $5.5 million grant from the Eli Lilly Foundation to support Destination 2032, a new initiative aimed at enhancing STEM education for IPS students.
Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...